Abstract
We assessed the anti-inflammatory, anti-oxidative and anti-remodeling impacts of a synthesized myrtenol-loaded niosome in rats with allergic asthma. Forty-nine rats were divided into seven groups of control, vacant niosome (VN), Asthma, Asthma+VN, Asthma+SM (simple myrtenol), Asthma+NM (niosomal myrtenol, 8 mg/kg), and Asthma+B (budesonide, 41 μg). Ovalbumin-induced asthmatic animals were exposed to daily inhalation of drug/vehicle for one week. Histopathology and inflammatory and oxidative stress indices in the lungs were assessed. Myrtenol-loaded niosomes showed appropriate physicochemical properties. Airway smooth muscle thickness, inflammatory cell infiltration, goblet cell hyperplasia, NO, IL-17, and MDA level decreased, and IL-10 and TAC levels increased in tissue and/or BALF of treatment groups. Niosomal myrtenol showed high potency comparable to budesonide in alleviating disease parameters. In conclusion, inhalation of niosomal myrtenol ameliorated inflammation, oxidative stress and tissue remodeling in asthmatic animals more potently than simple myrtenol and could be a target for production of an anti-asthmatic medicine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
